Canaan Partners X LLC's Q3 2020 13F: 1 position resized, no new positions or exits
Form 13F-HR for the quarter ended Sep 30, 2020 · filed Oct 26, 2020 · 3 reported positions · accession 0000950123-20-010459
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Reduced | NextCure Inc (NXTC) | 52.2% | 29.9% | −22.2 pts | −317K sh | −16% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
No changes in the top 10 this quarter
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | IDEAYA Biosciences Inc (IDYA) | 45.4% | 66.4% | |
| 2 | NextCure Inc (NXTC) | 52.2% | 29.9% | |
| 3 | Iterum Therapeutics plc (ITRM) | 2.5% | 3.6% |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).